Last reviewed · How we verify
NCT05334888: XCVD
Sex-differential Host-microbiome CVD Risk - A Longitudinal Cohort Approach
trial in Transgender in 200 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 29 August 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Germany |
Conditions studied
- Transgender — all drugs for Transgender →
- Gut Microbiome — all drugs for Gut Microbiome →
- Immune System — all drugs for Immune System →
- Cardiovascular Risk Factors — all drugs for Cardiovascular Risk Factors →
Sponsor
Charite University, Berlin, Germany
Who can join
Adults 18 to 50, any sex, with Transgender or Gut Microbiome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The XCVD study investigates the influence of sex hormones on the composition of the gut microbiome and the possible emergence of cardiovascular risk factors. It will follow 200 healthy transgender individuals for two years during their hormone replacement therapy (HRT) and analyze them for the possible emergence of cardiovascular risk factors in relation to changes in the gut microbiome, metabolome, and immunome. We would also like to phenotype cardiovascular disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sex hormone-dependent host-microbiome interactions and cardiovascular risk (XCVD): design of a longitudinal multi-omics cohort study.
Franz K, Markó L, Mähler A, Chakaroun R, et al · · 2025 · PMID 39788783 · DOI 10.1136/bmjopen-2024-087982
Verify or expand the search:
- PubMed search for NCT05334888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transgender
Currently open trials in the same condition.
- NCT07075731 — Cervical and Endometrial Cancer Screening in Patients Seeking Gender-Affirming Hysterectomy · recruiting
- NCT05318755 — China Gender-affirming Hormone Therapy Study · recruiting
- NCT04977765 — Cardiometabolic Health in Transgender Males · active not recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05334888 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05334888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing